Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

(2013) Philip J. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

(2013) Josep M. Llovet et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

(2012) R. S. Finn et al.   CLINICAL CANCER RESEARCH

Chemoembolization for Hepatocellular Carcinoma

(2012) Riccardo Lencioni   SEMINARS IN ONCOLOGY

Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

(2011) J.-W. Park et al.   CLINICAL CANCER RESEARCH

Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition

(2011) Elizabeth Allen et al.   CLINICAL CANCER RESEARCH

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

(2011) Masatoshi Kudo et al.   EUROPEAN JOURNAL OF CANCER

The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases

(2010) R. S. Bhide et al.   MOLECULAR CANCER THERAPEUTICS

Hypoxia: A Link between Fibrogenesis, Angiogenesis, and Carcinogenesis in Liver Disease

(2010) Olivier Rosmorduc et al.   SEMINARS IN LIVER DISEASE

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis

(2009) S J Schoenleber et al.   BRITISH JOURNAL OF CANCER

Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness

(2008) Adriana Sergio et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma

(2008) H. Huynh et al.   CLINICAL CANCER RESEARCH

Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease

(2008) Bruno M Strebel et al.   Expert Review of Anticancer Therapy

Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)

(2008) Zhen-wei Cai et al.   JOURNAL OF MEDICINAL CHEMISTRY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE